Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors

NCT01055067 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01055067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Terminated
Start date
February 2, 2010
Completion date
November 30, 2011
Enrollment
27 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-cns germ cell tumors (seminomas and nonseminomas)